Myriad Genetics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Myriad Genetics generated cash of -$110,900,000, which is less than the previous year. Cash used in financing activities reached the amount of $152,900,000 last year. Net change in cash is therefore $74,500,000.
Cash Flow
| 2016 | 166.3M | -91.4M | -68.3M |
|---|---|---|---|
| 2018 | 115.9M | -11.6M | -95M |
| 2020 | 83.7M | -286.4M | 182.3M |
| 2020 | -26.9M | 61.6M | -1M |
| 2021 | 18.2M | 274.4M | -150.6M |
| 2023 | -110.9M | 31.9M | 152.9M |
0K3W.L Cash Flow Statement (2015 – 2023)
| 2023 | 2021 | 2020 | 2019 | 2017 | 2015 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 66.4M | 117M | 93.2M | 110.9M | 102.4M | 64.1M |
Operating activities | ||||||
Net income | -263.3M | -27.2M | -223.7M | 4.6M | 131M | 125.3M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 61.9M | 62.8M | 71.4M | 73M | 54.4M | 26.7M |
Stock-based compensation expense | 40.7M | 36.3M | 24.3M | 33.5M | 27.1M | 31.6M |
| Deferred income tax benefit | 40.7M | 36.3M | 24.3M | 33.5M | 27.1M | 31.6M |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | 3.8M | -8.8M | 28.9M | -18.2M | -39.2M | -39.2M |
Inventories | -1.8M | 1.6M | 1.3M | 8M | 7.9M | -14.6M |
Accounts payable | -3.7M | 9.2M | 0 | 1.1M | 4M | -11.4M |
Cash generated by operating activities | -110.9M | 18.2M | -26.9M | 83.7M | 115.9M | 166.3M |
Investing activities | ||||||
Purchases Of Investments | 0 | -147.8M | 0 | -78.5M | -80.9M | -164.5M |
Investments In Property Plant And Equipment | -73.3M | -18M | -13.2M | -8.6M | -8.4M | -5M |
Acquisitions Net | 0 | 379.1M | 0 | -278.5M | 8.4M | -37M |
Cash generated by investing activities | 31.9M | 274.4M | 61.6M | -286.4M | -11.6M | -91.4M |
Financing activities | ||||||
Common Stock Issued | 117.6M | 91.8M | 0 | 8.7M | 36.9M | 0 |
Payments for dividends | 0 | 0 | 0 | -340M | 0 | 0 |
Repurchases of common stock | 0 | 0 | -3.9M | -50M | 0 | -162.6M |
Repayments of term debt | 39.8M | -226.4M | -8.6M | -115M | -143M | 0 |
Cash used in financing activities | 152.9M | -150.6M | -1M | 182.3M | -95M | -68.3M |
Net Change In Cash | 74.5M | 141.4M | 70.5M | -17.7M | 8.5M | 4.4M |
Cash at end of period | 140.9M | 258.4M | 163.7M | 93.2M | 110.9M | 68.5M |
| Data source | Data source | Data source | Data source | Data source |